GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Cyclically Adjusted PB Ratio

Cellectis (LTS:0WA2) Cyclically Adjusted PB Ratio : 0.39 (As of Jun. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Cellectis's current share price is €2.415. Cellectis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €6.16. Cellectis's Cyclically Adjusted PB Ratio for today is 0.39.

The historical rank and industry rank for Cellectis's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0WA2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.15   Med: 0.43   Max: 2.86
Current: 0.39

During the past years, Cellectis's highest Cyclically Adjusted PB Ratio was 2.86. The lowest was 0.15. And the median was 0.43.

LTS:0WA2's Cyclically Adjusted PB Ratio is ranked better than
76.83% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs LTS:0WA2: 0.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cellectis's adjusted book value per share data for the three months ended in Mar. 2024 was €1.158. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.16 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cellectis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Cyclically Adjusted PB Ratio Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.21 0.32 0.45

Cellectis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.29 0.24 0.45 0.40

Competitive Comparison of Cellectis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PB Ratio falls into.



Cellectis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cellectis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.415/6.16
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cellectis's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.158/119.4700*119.4700
=1.158

Current CPI (Mar. 2024) = 119.4700.

Cellectis Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.131 99.800 0.157
201406 0.825 100.180 0.984
201412 2.036 99.860 2.436
201503 8.899 100.170 10.614
201506 6.928 100.440 8.241
201509 6.843 99.950 8.179
201512 7.500 100.040 8.957
201603 7.081 100.020 8.458
201606 7.141 100.630 8.478
201609 7.174 100.340 8.542
201612 7.319 100.650 8.688
201703 7.124 101.170 8.413
201706 6.648 101.320 7.839
201709 6.595 101.330 7.776
201712 6.224 101.850 7.301
201803 5.741 102.750 6.675
201806 9.038 103.370 10.446
201809 8.698 103.560 10.034
201812 8.479 103.470 9.790
201903 8.159 103.890 9.383
201906 7.586 104.580 8.666
201909 7.287 104.500 8.331
201912 6.679 104.980 7.601
202003 7.072 104.590 8.078
202006 6.429 104.790 7.330
202009 5.802 104.550 6.630
202012 5.453 104.960 6.207
202103 5.112 105.750 5.775
202106 5.037 106.340 5.659
202109 4.448 106.810 4.975
202112 4.306 107.850 4.770
202203 3.813 110.490 4.123
202206 3.511 112.550 3.727
202209 3.029 112.740 3.210
202212 2.438 114.160 2.551
202303 1.911 116.790 1.955
202306 1.603 117.650 1.628
202309 1.283 118.260 1.296
202312 1.082 118.390 1.092
202403 1.158 119.470 1.158

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectis  (LTS:0WA2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cellectis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cellectis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (LTS:0WA2) Business Description

Industry
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (LTS:0WA2) Headlines

No Headlines